Wolfe Laboratories
| Company type | Private |
|---|---|
| Industry | Contract research organization (CRO) |
| Founded | 1999 |
| Founder | Dr. Janet Wolfe |
| Fate | Acquired by Pace Analytical in 2017; now operates as Pace Analytical Life Sciences, LLC |
| Headquarters | Woburn , United States |
Area served | Regional and global clients |
| Products | Research and development, GLP analytical services, formulation development, in-vitro ADME screening, pharmacokinetics assistance, API characterization, stability evaluations, consulting |
Wolfe Laboratories, Inc. (WLI) was a contract research organization (CRO) headquartered in Woburn, Massachusetts, delivering research and development along with GLP analytical services spanning from late discovery through early clinical phases of drug development. Operating from a dedicated site, WLI catered to both regional and global clients.
Following its acquisition by Pace Analytical in 2017, the company now functions under the name Pace Analytical Life Sciences, LLC.
Background
Established in 1999 by Dr. Janet Wolfe, who previously served as a Pharmaceutical Chemistry professor at the University of Tennessee, WLI was created to fulfill gaps in analytical method development and formulation offerings within pharmaceutical and biotechnology industries. Situated in the Boston area’s biotechnology cluster, WLI leveraged the growing tendency toward outsourcing in drug development processes.
The firm provided a range of services including pre-formulation and formulation development, expert consulting, pharmacokinetics assistance, in-vitro ADME screening, API characterization, stability evaluations, and GLP-compliant contract research. Its clientele spanned from emerging biotech enterprises to well-established pharmaceutical companies.
In 2006, WLI earned recognition as one of the "Top 100 Woman-Led Businesses in Massachusetts," ranked by revenue performance.
Role
Focusing on the drug development interval bridging discovery and clinical trials—a stage identified by the FDA as essential in the pathway to medical product approval—WLI distinguished itself among independent CROs by combining formulation development with in-vitro ADME/PK laboratory capabilities.
Traditionally, insufficient attention to this translational phase contributed to elevated failure rates during clinical testing due to suboptimal physicochemical and ADME characteristics. WLI assisted clients by thoroughly characterizing these properties that often cause attrition, such as limited solubility and chemical instability. Additionally, the company assessed safety-related parameters including bioavailability, interactions with the Cytochrome P450 enzyme system, and clearance rates to enhance drug candidates’ suitability for human administration.
Solubility
Effective drug delivery largely depends on compatibility with the body's aqueous environment. WLI specialized in rescuing and refining challenging drug candidates to ensure their viability for both animal models and human applications. The company demonstrated expertise in handling complex formulations requiring excipients to improve compound solubility—an essential process for clients advancing toward in vivo studies.